Monday, 17 August 2026European Markets
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agent Rollout Outpaces Data Trust and Readiness
Enterprise adoption of agentic AI is accelerating fast — Siemens deepening its NVIDIA partnership for self-verifying agentic AI in chip design, Manulife expanding its Microsoft AI-governance partnership, and a wave of infrastructure launches (NVIDIA GPU-accelerated data processing, Dell exascale storage, new AI chip generations) — even as a new Google Cloud survey shows the underlying data foundation isn't ready: companies have AI access to only 45% of their data on average, data laggards see access fall to 30% or less, and only about half of organizations trust their AI agents' decisions. Meanwhile, insider selling at enterprise-AI bellwether C3.ai (CEO Thomas Siebel offloading $4.8M in shares) hints at investor caution layered under the adoption hype.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,810
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,810 facts checked against source5,217 source documents archived
Work with this data → vianewsagency.com

ADOCIA Stock Bullish Momentum With A 15.98% Jump On Wednesday

Loading stream...

(vianews) - the market ended the session with adocia (adoc.pa) rising 15.98% to €11.90 on wednesday while cac 40 jumped 0.04% to €7,571.82.

adocia's last close was €10.26, 36.51% below its 52-week high of €16.16.

about adocia

adocia sa, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. its proprietary biochaperone technological platform provides molecular delivery of therapeutic proteins. the company's clinical product pipeline includes insulin formulations, such as biochaperone lispro u100 and u200, which are ultra-rapid formulations based on rapid insulin lispro; biochaperone combo, a combination of acting insulin glargine and rapid-acting insulin lispro; biochaperone lispram, a combination of prandial insulin with pramlintide; and biochaperone glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as m1pram, a metabolite of insulin glargine and pramlintide. its preclinical pipeline includes products for the treatment of diabetes and obesity comprising adoshell islets, an implant containing islets of langerhans; adoral sema, an oral delivery of semaglutide; and biochaperone gluexe, a combination of glucagon and exenatide. the company has a strategic alliance with tonghua dongbao pharmaceutical co., ltd. to develop and commercialize biochaperone lispro and biochaperone combo in china and other asian and middle eastern territories. adocia sa was incorporated in 2005 and is headquartered in lyon, france.

earnings per share

as for profitability, adocia has a trailing twelve months eps of €-2.5.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, adocia's stock is considered to be overbought (>=80).

volume

today's last reported volume for adocia is 363923 which is 103.38% above its average volume of 178937.

yearly top and bottom value

adocia's stock is valued at €11.90 at 21:30 est, way below its 52-week high of €16.16 and way higher than its 52-week low of €2.74.

more news about adocia (adoc.pa).